Cargando…

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice

BACKGROUND: The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Belmonte, Luis M., Sanz-Cánovas, Jaime, García de Lucas, María D., Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A., López-Sampalo, Almudena, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio, Miramontes-González, José P., Gómez-Huelgas, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263111/ https://www.ncbi.nlm.nih.gov/pubmed/35813629 http://dx.doi.org/10.3389/fendo.2022.851035

Ejemplares similares

Remission of type 2 diabetes: A critical appraisal
por: Ricci, Michele, et al.
Publicado: (2023)

Statin Therapy in Very Old Patients: Lights and Shadows
por: Cobos-Palacios, Lidia, et al.
Publicado: (2021)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia
por: Sanz-Cánovas, Jaime, et al.
Publicado: (2022)

COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia
por: López-Sampalo, Almudena, et al.
Publicado: (2023)

Statins and Peripheral Arterial Disease: A Narrative Review
por: Jansen-Chaparro, Sergio, et al.
Publicado: (2021)

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

Obesity, Diabetes, and Cardiovascular Risk Burden in Systemic Lupus Erythematosus: Current Approaches and Knowledge Gaps—A Rapid Scoping Review
por: Hernández-Negrín, Halbert, et al.
Publicado: (2022)

Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2020)

Lifestyle Modification Program on a Metabolically Healthy Elderly Population with Overweight/Obesity, Young-Old vs. Old-Old. CONSEQUENCES of COVID-19 Lockdown in This Program
por: Cobos-Palacios, Lidia, et al.
Publicado: (2021)

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
por: Aviles Bueno, Beatriz, et al.
Publicado: (2022)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
por: García de Lucas, María Dolores, et al.
Publicado: (2023)

Metabolically healthy obesity: Inflammatory biomarkers and adipokines in elderly population
por: Cobos-Palacios, Lidia, et al.
Publicado: (2022)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Síndrome de COVID-19 persistente. Una revisión narrativa
por: López-Sampalo, A., et al.
Publicado: (2022)

Persistent COVID-19 syndrome. A narrative review()
por: López-Sampalo, A., et al.
Publicado: (2022)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

Effectiveness of a cardiac rehabilitation program on biomechanical, imaging, and physiological biomarkers in elderly patients with heart failure with preserved ejection fraction (HFpEF): FUNNEL + study protocol
por: Cuesta-Vargas, Antonio Ignacio, et al.
Publicado: (2023)

Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain()
por: Salinas-Botrán, A., et al.
Publicado: (2022)

Características clínicas y factores de riesgo de mortalidad al ingreso en pacientes con insuficiencia cardíaca hospitalizados por COVID-19 en España
por: Salinas-Botrán, A., et al.
Publicado: (2022)

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Relationship between quadriceps femoris muscle architecture and muscle strength and physical function in older adults with heart failure with preserved ejection fraction
por: Fuentes-Abolafio, Iván J., et al.
Publicado: (2022)

Biomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional study
por: Fuentes-Abolafio, Iván José, et al.
Publicado: (2022)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
por: Martínez-Montoro, José Ignacio, et al.
Publicado: (2022)

Trends in Diabetes-Related Potentially Preventable Hospitalizations in Adult Population in Spain, 1997–2015: A Nation-Wide Population-Based Study
por: Gómez-Huelgas, Ricardo, et al.
Publicado: (2019)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
por: Dagli, Namrata, et al.
Publicado: (2023)

Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
por: Volpe, Sara, et al.
Publicado: (2023)

Adipokines Profile and Inflammation Biomarkers in Prepubertal Population with Obesity and Healthy Metabolic State
por: Cobos-Palacios, Lidia, et al.
Publicado: (2022)

Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
por: Anam, Mahvish, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5sis5ef02ipblu3gco4ft3mie